

Virginia Ferraresi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/678887/publications.pdf>

Version: 2024-02-01

81
papers

10,398
citations

136885

32
h-index

64755

79
g-index

83
all docs

83
docs citations

83
times ranked

12538
citing authors

#	ARTICLE	IF	CITATIONS
1	Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial. <i>Cancer</i> , 2022, 128, 85-93.	2.0	46
2	Prognostic value of total metabolic tumour volume and therapy-response assessment by [18F]FDG PET/CT in patients with metastatic melanoma treated with BRAF/MEK inhibitors. <i>European Radiology</i> , 2022, 32, 3398-3407.	2.3	8
3	Phase 2 study for nonmetastatic extremity high-grade osteosarcoma in pediatric and adolescent and young adult patients with a risk-adapted strategy based on ABCB1/P-glycoprotein expression: An Italian Sarcoma Group trial (ISG/OS-2). <i>Cancer</i> , 2022, 128, 1958-1966.	2.0	12
4	Neoadjuvant immune checkpoint inhibitors in high-risk stage III melanoma. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-11.	1.4	3
5	SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 148.	3.5	10
6	Symptoms and their implications on quality of life and psychological distress in sarcoma patients. <i>Future Oncology</i> , 2021, 17, 817-823.	1.1	6
7	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , 2021, 22, 655-664.	5.1	37
8	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , 2021, 22, 643-654.	5.1	224
9	CT radiomics-based machine learning classification of atypical cartilaginous tumours and appendicular chondrosarcomas. <i>EBioMedicine</i> , 2021, 68, 103407.	2.7	35
10	Outcome in dedifferentiated chondrosarcoma for patients treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study. <i>European Journal of Cancer</i> , 2021, 151, 150-158.	1.3	19
11	Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy). <i>Targeted Oncology</i> , 2021, 16, 789-799.	1.7	5
12	An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival. <i>Frontiers in Oncology</i> , 2020, 10, 1652.	1.3	10
13	Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover. <i>Cancers</i> , 2020, 12, 1727.	1.7	36
14	PTEN Function at the Interface between Cancer and Tumor Microenvironment: Implications for Response to Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5337.	1.8	26
15	Diagnostic and Clinical Impact of 18F-FDG PET/CT in Staging and Restaging Soft-Tissue Sarcomas of the Extremities and Trunk: Mono-Institutional Retrospective Study of a Sarcoma Referral Center. <i>Journal of Clinical Medicine</i> , 2020, 9, 2549.	1.0	20
16	The Real-Life Journey of Elderly Patients in Soft Tissue and Bone Sarcomas: A Retrospective Analysis from a Sarcoma Referral Center. <i>Journal of Clinical Medicine</i> , 2020, 9, 2503.	1.0	0
17	Desmoid Tumors Characteristics, Clinical Management, Active Surveillance, and Description of Our FAP Case Series. <i>Journal of Clinical Medicine</i> , 2020, 9, 4012.	1.0	10
18	Quality assessment of a clinical next-generation sequencing melanoma panel within the Italian Melanoma Intergroup (IMI). <i>Diagnostic Pathology</i> , 2020, 15, 143.	0.9	0

#	ARTICLE	IF	CITATIONS
19	Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISC), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. <i>Journal of Clinical Oncology</i> , 2020, 38, 2178-2186.	0.8	145
20	Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma. , 2020, 8, e000391.		39
21	Reorganization Tips from a Sarcoma Unit at Time of the COVID-19 Pandemic in Italy: Early Experience from a Regional Referral Oncologic Center. <i>Journal of Clinical Medicine</i> , 2020, 9, 1868.	1.0	11
22	Clinical and Immunological Outcomes in High-Risk Resected Melanoma Patients Receiving Peptide-Based Vaccination and Interferon Alpha, With or Without Dacarbazine Preconditioning: A Phase II Study. <i>Frontiers in Oncology</i> , 2020, 10, 202.	1.3	6
23	Comparison of 18F-FDG PET/CT Criteria for the Prediction of Therapy Response and Clinical Outcome in Patients With Metastatic Melanoma Treated With Ipilimumab and PD-1 Inhibitors. <i>Clinical Nuclear Medicine</i> , 2020, 45, 187-194.	0.7	31
24	18F-FDG PET/CT in the evaluation of cartilaginous bone neoplasms: the added value of tumor grading. <i>Annals of Nuclear Medicine</i> , 2019, 33, 813-821.	1.2	23
25	Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. <i>European Journal of Cancer</i> , 2019, 119, 1-10.	1.3	132
26	Sarcoma patientsâ€™ quality of life from diagnosis to yearly follow-up: experience from an Italian tertiary care center. <i>Future Oncology</i> , 2019, 15, 3125-3134.	1.1	5
27	Impact of Antiretroviral Therapy on the Risk of Recurrence in HIV-1 Infected Patients with Kaposi Sarcoma: A Multicenter Cohort Experience. <i>Journal of Clinical Medicine</i> , 2019, 8, 2062.	1.0	5
28	Histone deacetylase inhibitor ITF2357 leads to apoptosis and enhances doxorubicin cytotoxicity in preclinical models of human sarcoma. <i>Oncogenesis</i> , 2018, 7, 20.	2.1	20
29	Intralesional vs. extralesional procedures for low-grade central chondrosarcoma: a systematic review of the literature. <i>Archives of Orthopaedic and Trauma Surgery</i> , 2018, 138, 929-937.	1.3	23
30	EURO-B.O.S.S.: A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma. <i>Tumori</i> , 2018, 104, 30-36.	0.6	84
31	Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 639-648.	5.1	81
32	Bone sarcomas: ESMOâ€™PaedCanâ€™EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv79-iv95.	0.6	380
33	Antigen-specificity and DTIC before peptide-vaccination differently shape immune-checkpoint expression pattern, anti-tumor functionality and TCR repertoire in melanoma patients. <i>Oncolmmunology</i> , 2018, 7, e1465163.	2.1	6
34	Gastrointestinal stromal tumours: ESMOâ€™EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv68-iv78.	0.6	413
35	Soft tissue and visceral sarcomas: ESMOâ€™EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv51-iv67.	0.6	641
36	Fibrous dysplasia: an unusual case of a very aggressive form with costo-vertebral joint destruction and invasion of the contralateral D7 vertebral body. <i>Skeletal Radiology</i> , 2018, 47, 1571-1576.	1.2	1

#	ARTICLE	IF	CITATIONS
37	HMGA1/E2F1 axis and NFκB pathways regulate LPS progression and trabectedin resistance. <i>Oncogene</i> , 2018, 37, 5926-5938.	2.6	24
38	Precision diagnostics of Ewing's sarcoma by liquid biopsy: circulating <i>EWS-FLI1</i> fusion transcripts. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591877433.	1.4	26
39	Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 393-403.	5.1	91
40	Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-ST5 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. <i>Lancet Oncology</i> , The, 2017, 18, 812-822.	5.1	370
41	Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 611-622.	5.1	428
42	Polyfunctional Melan-A-specific tumor-reactive CD8 ⁺ T cells elicited by dacarbazine treatment before peptide-vaccination depends on AKT activation sustained by ICOS. <i>Oncolmunology</i> , 2016, 5, e1114203.	2.1	25
43	Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. <i>New England Journal of Medicine</i> , 2016, 375, 1845-1855.	13.9	1,140
44	Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet</i> , The, 2015, 386, 444-451.	6.3	1,175
45	Bilateral spontaneous pneumothorax and massive pneumomediastinum under pazopanib therapy. <i>Thoracic Cancer</i> , 2015, 6, 110-111.	0.8	2
46	Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. <i>Lancet Oncology</i> , The, 2015, 16, 98-107.	5.1	270
47	Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC Tj ETQq1 1 0,784314 rrgBT /Overle	5.1	1,093
48	miR-181c associates with tumor relapse of high grade osteosarcoma. <i>Oncotarget</i> , 2015, 6, 13946-13961.	0.8	20
49	Familial Kaposi's Sarcoma in HHV8 infected subjects presenting the G-174C allele of the IL-6 promoter: a possible role for EBV?. <i>European Journal of Dermatology</i> , 2014, 24, 503-504.	0.3	4
50	Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program. <i>Cancer Investigation</i> , 2014, 32, 144-149.	0.6	90
51	Giant cell tumor of bone in a patient with diagnosis of primary hyperparathyroidism: a challenge in differential diagnosis with brown tumor. <i>Skeletal Radiology</i> , 2014, 43, 693-697.	1.2	24
52	Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. <i>Journal of Neuro-Oncology</i> , 2014, 118, 109-116.	1.4	103
53	Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. <i>New England Journal of Medicine</i> , 2014, 371, 1877-1888.	13.9	1,572
54	A multiplanar complex resection of a low-grade chondrosarcoma of the distal femur guided by K-wires previously inserted under CT-guide: a case report. <i>BMC Surgery</i> , 2014, 14, 52.	0.6	4

#	ARTICLE	IF	CITATIONS
55	Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 675-683.	2.0	230
56	Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma. <i>European Journal of Cancer</i> , 2014, 50, 121-127.	1.3	149
57	Nonmetastatic osteosarcoma of the extremity. Neoadjuvant chemotherapy with methotrexate, cisplatin, doxorubicin and ifosfamide. An Italian Sarcoma Group study (ISG/OS-Oss). <i>Tumori</i> , 2014, 100, 612-619.	0.6	17
58	Nonmetastatic osteosarcoma of the extremity. Neoadjuvant chemotherapy with methotrexate, cisplatin, doxorubicin and ifosfamide. An Italian Sarcoma Group study (ISG/OS-Oss). <i>Tumori</i> , 2014, 100, 612-9.	0.6	17
59	Radiation recall dermatitis in course of epidemic Kaposi's sarcoma. <i>Dermatologic Therapy</i> , 2013, 26, n/a-n/a.	0.8	0
60	Diagnostic and Therapeutic Approaches in Italian Hospitals: Adjuvant and Metastatic Therapy in Melanoma. <i>Dermatology</i> , 2013, 226, 22-27.	0.9	4
61	Italian cohort of ipilimumab expanded access programme (EAP): Efficacy, safety, and correlation with mutation status in metastatic melanoma patients.. <i>Journal of Clinical Oncology</i> , 2013, 31, 9070-9070.	0.8	9
62	Chemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma. The SARcoma treatment and Burden of Illness in North America and Europe (SABINE) study. <i>Annals of Oncology</i> , 2012, 23, 2763-2770.	0.6	61
63	Phase II Study of Imatinib in Advanced Chordoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 914-920.	0.8	230
64	Chemotherapeutically Induced Cutaneous Tuberculosis after BCG Injection in a Patient with Pelvic Osteosarcoma. <i>Surgical Infections</i> , 2012, 13, 406-408.	0.7	3
65	¹⁵³ Samarium-EDTMP administration followed by hematopoietic stem cell support for bone metastases in osteosarcoma patients. <i>Annals of Oncology</i> , 2012, 23, 1899-1905.	0.6	25
66	A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor α or β . <i>Cancer</i> , 2011, 117, 826-831.	2.0	42
67	Antiepileptics in brain metastases: safety, efficacy and impact on life expectancy. <i>Journal of Neuro-Oncology</i> , 2010, 98, 109-116.	1.4	38
68	Chordoma: clinical characteristics, management and prognosis of a case series of 25 patients. <i>BMC Cancer</i> , 2010, 10, 22.	1.1	108
69	Dacarbazine Treatment before Peptide Vaccination Enlarges T-Cell Repertoire Diversity of Melan-A-Specific, Tumor-Reactive CTL in Melanoma Patients. <i>Cancer Research</i> , 2010, 70, 7084-7092.	0.4	57
70	Large Randomized Study of Thymosin α 1, Interferon Alfa, or Both in Combination With Dacarbazine in Patients With Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 1780-1787.	0.8	62
71	Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients. <i>International Journal of Cancer</i> , 2009, 124, 130-139.	2.3	103
72	An osteoporotic hip fracture in a 14-year-old girl undergoing chemotherapy and operated for knee osteosarcoma. <i>Journal of Orthopaedics and Traumatology</i> , 2009, 10, 151-154.	1.0	1

#	ARTICLE	IF	CITATIONS
73	Gemcitabine at fixed dose-rate in patients with advanced soft tissue sarcomas: a mono-institutional phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 63, 149-155.	1.1	27
74	A phase II trial of gefitinib in combination with capecitabine and oxaliplatin as first-line chemotherapy in patients with advanced colorectal cancer. <i>Current Medical Research and Opinion</i> , 2007, 23, 2117-2123.	0.9	12
75	Central nervous system as exclusive site of disease in patients with melanoma: treatment and clinical outcome of two cases. <i>Melanoma Research</i> , 2005, 15, 467-469.	0.6	13
76	Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer. <i>Annals of Oncology</i> , 2003, 14, 1378-1382.	0.6	54
77	Weekly schedule of vinorelbine in pretreated breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2000, 59, 223-229.	1.1	21
78	Toxicity and Activity of Docetaxel in Anthracycline-Pretreated Breast Cancer Patients. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2000, 23, 132-139.	0.6	39
79	Ifosfamide, cisplatin and etoposide combination in locally advanced inoperable non-small-cell lung cancer: a phase II study. <i>British Journal of Cancer</i> , 1999, 81, 1031-1036.	2.9	9
80	Breast cancer and timing of surgery during menstrual cycle: a 5-year analysis of 248 premenopausal women. <i>Breast Cancer Research and Treatment</i> , 1999, 55, 259-266.	1.1	13
81	Phase II trial of high-dose epirubicin and cyclophosphamide in advanced breast cancer. <i>European Journal of Cancer</i> , 1994, 30, 1285-1288.	1.3	11